Welcome to our dedicated page for Rezolute SEC filings (Ticker: RZLT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rezolute, Inc. (Nasdaq: RZLT) SEC filings page provides access to the company’s regulatory disclosures as a publicly traded, late-stage rare disease company focused on hypoglycemia caused by hyperinsulinism. Through these documents, investors can review how Rezolute reports on its clinical programs, financial condition, governance and shareholder matters.
Current reports on Form 8-K include items such as clinical and business updates, financial results, and corporate actions. For example, recent 8-K filings reference press releases on quarterly and annual financial results, alignment with the U.S. Food and Drug Administration on the design of the Phase 3 upLIFT study in tumor hyperinsulinism, and updates on the ersodetug development program. Other 8-Ks describe material agreements, executive appointments, amendments to employment arrangements, and the termination of an at-the-market equity program.
Proxy materials, such as the definitive proxy statement on Schedule DEF 14A, outline proposals presented at Rezolute’s annual meeting of stockholders. These include the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation, amendments to the company’s equity incentive plan, and potential adjournment proposals. Related 8-K filings report the final voting results for these matters.
Investors can also use this page to locate filings that incorporate press releases on financial results, which provide additional context on research and development spending, general and administrative expenses, and net loss figures, as described by the company. While this page focuses on accessing the underlying SEC documents, AI-powered tools on the platform can help summarize key points from lengthy filings, highlight important sections, and make it easier to understand Rezolute’s disclosures on clinical progress, compensation policies and capital structure.
Together, these SEC filings form an official record of Rezolute’s activities as a Nasdaq-listed issuer developing its lead monoclonal antibody therapy, ersodetug, for congenital and tumor hyperinsulinism.
Rezolute, Inc. executive equity grants disclosed
Rezolute, Inc. reported that its Chief Financial Officer, Daron Evans, acquired 107,000 restricted stock units of Rezolute common shares on 11/19/2025 at a stated price of $0. These restricted stock units vest annually over a three-year period, with the first portion vesting on December 1, 2026.
Following this transaction, Evans beneficially owns 375,900 Rezolute common shares directly, with additional indirect holdings through family members and PoC Capital, LLC. He also received an employee stock option grant covering 63,000 Rezolute common shares at an exercise price of $10.16 per share, vesting 1/36th monthly beginning on December 19, 2025 and expiring on November 19, 2035.
Rezolute, Inc. filed a Form S-8 to cover its Amended and Restated 2021 Equity Incentive Plan, under which an aggregate of 21,950,000 shares of common stock are available for issuance. Shareholders approved the amendment to this equity plan on November 19, 2025, expanding the pool of shares that can be granted to employees, directors and other eligible participants. The filing incorporates prior S-8 registrations for the same plan and updates the total shares that may be issued as equity compensation.
Rezolute, Inc. director reports new equity awards. On 11/19/2025, a director of Rezolute, Inc. (RZLT) received 21,000 restricted stock units at a stated price of $0, increasing the director’s beneficial ownership to 58,576 common shares. The RSUs fully vest on December 1, 2026, meaning the director will receive the underlying shares only after that date if the vesting conditions are met.
The director also received a stock option grant to buy 12,000 common shares at an exercise price of $10.16 per share. These options are exercisable until November 19, 2035 and fully vest on December 1, 2026. Both awards are reported as directly owned and reflect standard equity-based compensation for board service.
Rezolute, Inc. reported an equity award to a director. A board member received 21,000 common shares in the form of restricted stock units on November 19, 2025, recorded at a price of $0, increasing their directly held stake to 114,025 common shares after the transaction. These restricted stock units fully vest on December 1, 2026.
The director was also granted a stock option covering 12,000 common shares at an exercise price of $10.16 per share, expiring on November 19, 2035. The option grant also fully vests on December 1, 2026, aligning both equity awards to the same vesting date.
Rezolute, Inc. (RZLT) reported a new equity compensation grant to one of its directors. On 11/19/2025, the reporting person acquired 21,000 common shares as a grant of restricted stock units at a price of $0, reflecting stock-based compensation rather than a purchase. After this transaction, the director beneficially owned 21,000 common shares directly.
On the same date, the director also received a stock option to buy 12,000 common shares at an exercise price of $10.16 per share, with the option expiring on 11/19/2035. Both the 21,000 restricted stock units and the 12,000 options are scheduled to fully vest on December 1, 2026, tying the director’s compensation to Rezolute’s future share performance.
Rezolute, Inc. reported results from its 2026 annual stockholder meeting. Stockholders elected all seven director nominees to the board, with each receiving a majority of votes cast. As of the record date of September 22, 2025, 90,811,368 shares of common stock were outstanding and 66,700,068 shares were represented at the meeting, establishing a quorum.
Stockholders ratified Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026. A non-binding say-on-pay proposal approving compensation for named executive officers also received stockholder approval. In addition, stockholders approved an amendment to the 2021 Stock Incentive Plan to increase the shares available for issuance from 14,450,000 to 21,950,000. An adjournment proposal related to the equity plan amendment was also approved but was not needed once the amendment passed.
Rezolute, Inc. (RZLT)21,000 restricted stock units at a price of $0, which fully vest on December 1, 2026. Following this grant, he directly beneficially owns 170,950 common shares. In addition, he indirectly beneficially owns 8,423,386 common shares held by Handok, Inc., for which he disclaims beneficial ownership except to the extent of any pecuniary interest.
Kim was also granted a director stock option to purchase 12,000 common shares at an exercise price of $10.16 per share, with the options fully vesting on December 1, 2026 and expiring on November 19, 2035. These awards increase his potential long‑term equity stake and further align his interests with Rezolute shareholders.
Rezolute, Inc. (RZLT) reported an equity grant to a director. On 11/19/2025, the director received 21,000 restricted stock units of Rezolute common shares at a price of $0, increasing their directly owned common shares to 55,500 after the transaction. The filing also reports a grant of a director stock option for 12,000 common shares at an exercise price of $10.16 per share, expiring on 11/19/2035.
The 21,000 restricted stock units fully vest on December 1, 2026, meaning the director will receive the underlying shares at that time if conditions are met. The 12,000 options become fully exercisable on December 1, 2026, giving the director the right to buy Rezolute shares at $10.16 per share through the expiration date.
Rezolute, Inc. (RZLT) reported an insider equity grant for director Gil M. Labrucherie. On 11/19/2025, he received 21,000 restricted stock units at a price of $0, which fully vest on December 1, 2026. Following this grant, he beneficially owns 55,500 common shares directly and 53,572 common shares indirectly through The Labrucherie Trust dated 9/1/2009.
He was also granted a director stock option for 12,000 common shares at an exercise price of $10.16 per share on 11/19/2025. These options are exercisable until 11/19/2035 and fully vest on December 1, 2026.
Rezolute, Inc. filed an 8-K noting it hosted an investor event and related presentation to provide an update on the Ersodetug development program.
The presentation is furnished as Exhibit 99.1 and is not deemed “filed” under the Exchange Act. The company included customary forward‑looking statements cautions and referred readers to its risk factors in prior SEC filings. Rezolute’s common stock trades on the Nasdaq Capital Market under the symbol RZLT.
FAQ
What is the current stock price of Rezolute (RZLT)?
What is the market cap of Rezolute (RZLT)?
